Efficacy and Safety of Trilaciclib in Myeloprotection during Chemotherapy for Pediatric Patients with Parameningeal Rhabdomyosarcoma with Meningeal Invasion

Efficacy and Safety of Trilaciclib in Myeloprotection during Chemotherapy for Pediatric Patients with Parameningeal Rhabdomyosarcoma with Meningeal Invasion: A prospective Single-arm Clinical Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500108628

Enrollment

Unknown

Registered

2025-09-02

Start date

2025-09-15

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhabdomyosarcoma

Interventions

Experimental group:Trilaciclib infusion

Eligibility

Sex/Gender

All

Age

1 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. 1 year old 16 years old) >=50%; 6. With measurable and/or evaluable lesions; 7. With sufficient organ function before chemotherapy.

Exclusion criteria

Exclusion criteria: 1. A history of or concurrent other malignant tumors; 2. Those with a known history of allergy to the components of Trilaciclib; 3. Recurrent patients who have previously received multiple cycles of chemotherapy; 4. Patients who have received radiotherapy; 5. According to the investigator's judgment, subjects have factors that should be excluded from this study, such as complicated with other serious diseases, severe abnormalities in laboratory results, or being unable to complete the study due to family, social and other factors.

Design outcomes

Primary

Measure	Time frame
Incidence of grade >=3 neutropenia;	—

Countries

China

Contacts

Public ContactYan Su

Beijing Children’s Hospital, Capital Medical University

suyanbch@sina.com+86 10 5961 2198

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026